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Abstract
The facile synthesis of seven new dicationic tripeptide benzyl ester derivatives, with hydrophobic group variations in the C-terminal
amino acid component, is described. Moderate to good activity was seen against Gram-positive bacteria in vitro. One cyclohexyl-
substituted compound 2c was tested more widely and showed good potency (MIC values ranging from 2–4 μg/mL) against anti-
biotic-resistant strains of Staphylococcus aureus and Enterococci (VRE, VSE), and against Staphylococcus epidermidis.
Introduction
Among the most pressing challenges in current healthcare is the
resistance of bacterial human pathogenic organisms to anti-
biotics [1,2], and of particular concern is the resistance to the
cationic glycopeptide, vancomycin [3,4]. This challenge is
being addressed in a number of ways, which include both
detailed studies aimed at the further understanding of the mech-
anism of this resistance, as well as the development of new
large glycopeptide analogues containing amine sites that can be
protonated, such as telavancin, oritavancin and dalbavancin [5].
An alternative approach to meeting this resistance challenge, at
least in part, is through the design and synthesis of smaller
cationic peptidic compounds incorporating features that could
circumvent the vancomycin resistance mechanism. In much of
our work we have been concerned with binaphthyl-based
dicationic peptide derivatives, for example the acyclic tripep-
tides of type 1 (Figure 1; for example A = CH2CH=CH2,
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Table 1: MIC values (μg/mL) against S. aureus, S. epidermidis and Enterococci of the tripeptide benzyl ester derivatives 2a–g and 9 [6] as their dihy-
drochloride salts.a
Compound S. aureus S. epidermidis VRE243 VRE449 VRE820 VRE987
2a 4 – 62 31 31 62
2b 3 – 62 31 31 62
2c 2 – 31 16 16 31
2d 3 3 >25 >25 >25 >25
2e 3 3 >25 >25 >25 >25
2f 3–6 3 25 25 12 25
2g 2 2 16 16 16 31
9 4 – 16 16 8 16
Vancomycin 2–3 3 2 >25 >25 3
aAll MIC values have been rounded to whole numbers.
B = CH2Ph, R = CH2CH2CH(CH3)2, MIC against S. aureus
4 μg/mL [6]), which show significant promise as antibacterials
[6-8]. In the development of these antibacterials, it became
apparent that the nature of the C-terminal amino acid derivative
was significant, with indications that the hydrophobic groups at
the terminus (Figure 1, group B) [6] and at the α-carbon of the
amino acid moiety (Figure 1, group A) [6,7] were important. In
further exploration of the structural space in the latter area,
while maintaining benzyl ester functionality at the terminus
itself (a free carboxylic acid unit at the C-terminal was delete-
rious to activity [8]), we envisaged the introduction of two alkyl
substituent units incorporated in a ring system at this carbon,
resulting in the target compounds 2a–d. Two further com-
pounds based on a β–alanine unit with disubstitution at the α- or
β-carbons of this unit, 2f and 2e respectively, were accessed
with a view to assessing the effect of variation in the spatial
disposition of the cycloalkyl or oxacycloalkyl ring on antibacte-
rial activity. The conformationally less restricted gem diethyl-
substituted compound 2g was also targeted in order to make
antibacterial activity comparisons with the five-membered ring
analogue 2b. The results of these synthetic and antibacterial
testing studies are reported in this paper.
Figure 1: Binaphthyl-anchored tripeptide derivatives 1.
Results and Discussion
A concise and flexible approach to all the target compounds
2a–g was used, starting from the commercially available amino
acid derivatives 3 and proceeding via the amino benzyl esters 4
(Scheme 1), with the exception of the synthesis of 2c in which
the commercially available 4c was used as the starting material.
Addition of the protected central arginine unit by diimide- or
BOP-induced amide bond formation, followed by selective
Fmoc removal from the respective intermediates 5, then
provided access to the key intermediate amines 6a–g
(Scheme 1). Diimide-mediated coupling of the previously
reported lysine containing (S)-binaphthyl acid derivative 7 [8]
then afforded the protected tripeptides 8a–g. Removal of the
Pmc (or Pbf) and Boc protecting groups in one pot was then
achieved by exposure to trifluoroacetic acid, followed by tri-
fluoroacetate/chloride ion exchange on treatment with an excess
of HCl in diethyl ether, and finally evaporation to afford the
salts 2a–g in good overall yields.
The structures of the final compounds were supported by 1H
and 13C NMR spectroscopy and high-resolution mass spectrom-
etry. Details of the synthesis and spectral data are given in the
experimental section for the representative compound 2c. The
experimental and spectroscopic data for all the other com-
pounds are included in Supporting Information File 1.
The peptidic dihydrochloride salts 2a–g were tested against the
Gram-positive bacteria Staphylococcus aureus (ATCC 6538)
and four clinical isolates of vancomycin-resistant (and sensi-
tive) enterococci (VRE; Enterococcus faecium), and the results
are shown in Table 1; some compounds were also tested against
Staphylococcus epidermidis (ATCC 12228). Vancomycin was
used as a positive control, and showed a rounded MIC
(minimum inhibitory concentration) value of 2–3 μg/mL against
S. aureus and MIC values of 2, >25, >25 and 3 μg/mL against
the vancomycin sensitive and partially resistant enterococci
Beilstein J. Org. Chem. 2012, 8, 1265–1270.
1267
Scheme 1: Synthesis of compounds 2a–g. Reagents and conditions: (i) 2a–b,d–g, BnBr, acetone or THF, K2CO3, reflux, 3–12 h; (ii) TFA, DCM, rt,
1–2 h, 2 M HCl/Et2O (HCl salts); (iii) 5a–f: (DIPEA), Fmoc-(R)-Arg(Pmc)-OH (5c) or Fmoc-(R)-Arg(Pbf)-OH (5a–b, d–f), EDCI, HOBt, CH3CN, rt,
3–16 h; 5g: DIPEA, Fmoc-(R)-Arg(Pbf)-OH, BOP, CH3CN, rt, 3–16 h (iv) piperidine, CH3CN, rt, 3–12 h; (v) EDCI, HOBt, CH3CN, rt, 3–72 h; (vi) TFA/
CH2Cl2 (1:1), rt, 2–16 h, then 2 M HCl/Et2O. *Isolated as the HCl salt.
strains, VRE243, VRE449, VRE820 and VRE987, respectively
(Table 1). For comparison purposes, data for the previously
reported [6] isobutyl-substituted analogue 9 (Table 2) are also
included.
While MIC micromolar values should be used for comparative
analysis of activities, the more commonly used concentration of
micrograms per milliliter is retained in this case. The micro-
molar values are barely different from the latter, as the molecu-
lar weights for all of the compounds are similar (959–1001;
vancomycin·HCl, 1486). In most cases, incorporation of a
hydrophobic alkyl ring in the chain adjacent to the ester func-
tionality results in good activity against S. aureus and
S. epidermidis, but a greater variation of activity was seen with
the enterococcal strains. The systems with four- and five-
membered cycloalkyl rings (2a and 2b) displayed similar activi-
ties, while the cyclohexyl analogue 2c was somewhat better.
Reducing the hydrophobicity while increasing the hydro-
philicity of the six-membered ring in 2c through inclusion of a
ring oxygen atom, as in 2d, had a significant detrimental effect
on the activity against the vancomycin-resistant strains VRE449
and VRE820. Interestingly, the placement of an extra methylene
group in the chain, either on the carboxylic ester side (2e) or the
amino side (2f), had no or little effect on antibacterial activity,
Beilstein J. Org. Chem. 2012, 8, 1265–1270.
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Table 2: MIC values of compounds 2c and 9 against Gram-positive
isolates.
Straina MIC50 (range) or MIC [μg/mL]b
2c 9 [6] Vancomycin
S. aureus
MSSA (8) 2–4 6 1–2
MRSA (7) 2–4 6 1–2
VISA (1) 4 6 6–8
S. epidermidis (3) 2 3 2–3
E. faecium
VRE (4) 4 2 >32
VSE (4) 2–4 16 2–8
aCompound 2c was tested against a variety of strains (number in
brackets) of S. aureus, S. epidermidis and E. faecium, while com-
pound 9 was tested against only one strain of each organism. Where
the MIC was the same for each strain, no range is given. bWhere only
one strain was tested, the value given is a MIC. S. epidermidis =
Staphylococcus epidermidis; E. faecium = Enterococcus faecium;
MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant
S. aureus; VISA = vancomycin-intermediate S. aureus; VRE =
vancomycin-resistant enterococci; VSE = vancomycin-sensitive entero-
cocci. MIC = minimum inhibitory concentration [μg/mL; rounded to
whole numbers].
regardless of whether a ring oxygen atom was present or not. It
appeared that moving the hydrophobic ring substituent position
by a small amount in the terminal amino acid unit could be
tolerated in these systems.
The diethyl-substituted peptide derivative 2g was more active
than the constrained ring comparator compound 2b against the
enterococci, including the vancomycin resistant isolates VRE449
and VRE820, but both had similarly good potencies against
S. aureus. In contrast, compound 2c with the cyclohexyl ring
was somewhat more active than the isobutyl-substituted ana-
logue 9. It would thus appear that greater coverage of the hydro-
phobic space available in this region is required for good to
moderate activity against both the staphylococci and entero-
cocci.
As a result of its promising initial activity profile, the tripeptide
derivative 2c was subjected to further evaluation (Table 2). It
was tested against methicillin-sensitive (MSSA), methicillin-
resistant (MRSA) and vancomycin-intermediate (VISA)
S. aureus, S. epidermis and vancomycin-resistant (VRE) and
vancomycin-sensitive (VSE) enterococci. The test compound 2c
showed good activity against all these Gram-positive bacteria
with MIC values in the range of 2–4 µg/mL. Again, for com-
parison purposes, results for the published analogue 9 [6],
containing a single isobutyl group in place of the cyclohexyl
group, are also included in Table 2. This tripeptide derivative 9
showed similar, if slightly weaker, antibacterial activity against
these strains, apart from VSE, against which it was signifi-
cantly less potent than 2c.
Although the mode of action of the tripeptide derivatives has
not been established, our earlier results on compounds of type 1
(Figure 1) and related cyclic systems implicated the possibility
of more than one mode of action [8]. As noted for other cationic
peptide derivatives [9-12], cell membrane damage could well be
one of these actions, together with some more specific interac-
tions. Dual-action type behaviour has been shown for the
vancomycin analogue telavancin, which affects cell wall syn-
thesis and the integrity of the cell membrane [13].
Conclusion
In conclusion, seven novel binaphthyl-anchored tripeptide
derivatives have been prepared and tested for antibacterial
activity against S. aureus and four clinical enterococcal strains.
The dicationic derivatives 2c and 2g showed the best overall
activities. In addition, compound 2c with a hydrophobic cyclo-
hexyl substituent originating from the α-position of the
C-terminal amino acid ester, showed good activity against
S. epidermidis and MSSA, MRSA, VISA and VRE organisms.
Our results confirmed the positive contribution to good Gram-
positive antibacterial activity, engendered by filling of a hydro-
phobic area close to the C-terminus of these acyclic tripeptide
derivatives.
Experimental
General notes were those detailed previously in the supporting
information for reference [8].
Benzyl 1-((R)-3-amino-1-aza-6-(3,4-dihydro-2,2,5,7,8-
pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]guanidino)-2-
oxohexan)cyclohexanecarboxylate (6c). This compound was
prepared in two steps. To a solution of the amine 4c [14]
(115 mg, 0.49 mmol) in CH3CN (5 mL) at rt was added HOBt
(1.2 equiv), EDCI (1.2 equiv) and the acid Fmoc-(R)-Arg(Pmc)-
OH [8] (318 mg, 0.48 mmol). The mixture was stirred for ca.
3 h, then the solvent was removed under reduced pressure, and
Beilstein J. Org. Chem. 2012, 8, 1265–1270.
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the resulting residue was subjected to silica gel column chroma-
tography (MeOH/CH2Cl2, 1:99–4:96 as the eluent) to afford the
Fmoc-protected precursor 5c as a white foamy solid (402 mg,
ESIMS m/z: [M + H]+ 877.9 (100%)). This precursor 5c
(200 mg, 0.238 mmol) was then directly deprotected by being
stirred in 1 equiv of piperidine/acetonitrile (5 mL per 0.1 mmol
of substrate) for 12 h at rt. The solvent was removed under
reduced pressure, and the crude product was purified by flash
column chromatography (silica gel; CH2Cl2/MeOH 15:1) to
afford the desired amine 6c as a white solid (141 mg, 87% two
steps). 1H NMR (500 MHz, CDCl3) δ 1.19–1.44 (m, 16H), 1.30
(s, 6H, 2CH3 (Pmc)), 2.34 (br s, NH2), 2.10 (s, 3H, CH3 (Pmc)),
2.57 (s, 3H, CH3 (Pmc)), 2.58 (s, 3H, CH3 (Pmc)), 2.61 (t, J =
6.5 Hz, 2H, CH2 (Pmc)), 3.05–3.29 (m, 2H, CH2N), 3.39–3.50
(m, 1H, CH (Arg)), 5.06 (ABq, J = 12.6 Hz, 1H), 5.09 (ABq, J
= 12.6 Hz, 1H), 6.41 (s, NH), 7.26–7.41 (m, 5H, ArH), 7.80 (s,
NH); 13C NMR (125 MHz, CDCl3) δ 12.0, 17.4, 18.4, 21.3,
24.5, 25.0, 25.3, 26.7, 26.75, 31.6, 31.9, 32.4, 32.7, 40.5, 54.1,
57.8, 58.4, 66.7, 73.5, 117.8, 123.9, 127.9, 128.1, 128.4, 133.3,
134.6, 135.3, 135.8, 153.4, 156.3, 174.0, 174.4; ESIMS m/z:





hexanecarboxylate (8c). To a solution of the amine 6c
(140 mg, 0.213 mmol) in CH3CN (10 mL) at rt was added
HOBt (1.2 equiv), EDCI (1.2 equiv) and the binaphthyl acid 7
[8] (122 mg, 0.190 mmol). The mixture was stirred for ca. 3 h.
The solvent was then removed under reduced pressure and the
resulting residue subjected to silica gel chromatography
(MeOH/CH2Cl2 1:99–4:96 as the eluent) to yield 8c as a white
solid (163 mg, 67%). [α]D
24 −18.6 (c 2.0, MeOH); 1H NMR
(300 MHz, CDCl3) δ 0.49 (d, J = 6.4 Hz, 3H), 0.54 (d, J = 6.4
Hz, 3H), 0.66–0.84 (m, 2H), 0.85–1.03 (m, 2H), 1.05–1.62 (m,
16H), 1.29 (s, 6H), 1.44 (s, 9H), 1.64–1.88 (m, 4H), 1.89–2.14
(m, 1H), 2.09 (s, 3H), 2.54–2.64 (m, 2H), 2.55 (s, 3H), 2.57 (s,
3H), 2.84–2.96 (m, 2H), 2.97–3.22 (m, 2H), 3.76–3.94 (m, 1H),
4.00–4.07 (m, 2H), 4.36 and 4.54 (ABq, J = 14.6 Hz, 2H),
4.39–4.48 (m, 1H), 4.78–4.82 (m, NH), 5.06 (s, 2H), 6.14 (br s,
NH) 6.36 (br s, NH), 7.11–7.46 (m, 12H), 7.44 (d, J = 9.1 Hz,
1H), 7.84 (d, J = 8.9 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.92 (d,
J = 8.8 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H); ESIMS m/z:
[M + H]+ 1280.3 (100%); HRMS–ESI m/z: [M + H]+ calcd for




(2c). The protected amine 8c (106 mg, 0.083 mmol) in 1:1
CH2Cl2/TFA (6 mL/0.10 mmol) solution was stirred for 12 h at
rt. The solvent was removed under reduced pressure, and the
residue was resuspended in a minimal volume of methanol. The
solution was then treated with an excess of 2 M HCl/diethyl
ether solution (2 mL, 0.01 mmol) and the solvent evaporated.
The crude product was purified by precipitation from MeOH by
addition of diethyl ether to yield 2c as an off white solid
(35 mg, 43%). [α]D
24 −10.9 (c 3.4, MeOH); 1H NMR (300
MHz, CD3OD) δ 0.50 (d, J = 6.4 Hz, 3H), 0.56 (d, J = 6.4 Hz,
3H), 0.84–1.02 (m, 2H), 1.03–3.15 (m, 21H), 2.68–2.92 (m,
2H), 2.96–3.20 (m, 2H), 3.91–3.98 (m, 1H), 4.09–4.16 (m, 2H),
4.24–4.36 (m, 1H), 4.42 and 4.54 (ABq, J = 14.6 Hz, 2H), 5.02
and 5.09 (ABq, J = 12.3 Hz, 2H), 7.06 (t, J = 5.5 Hz, 2H),
7.17–7.22 (m, 2H), 7.27–7.36 (m, 7H), 7.44 (d, J = 8.8 Hz, 1H),
7.53 (d, J = 9.1 Hz, 1H), 7.90 (t, J = 7.0 Hz, 2H), 8.00 (dd, J =
2.3 and 9.1 Hz, 2H), 8.09 (s, NH); 13C NMR (75 MHz,
CD3OD) δ 22.5, 22.6, 22.8, 23.0, 25.6, 26.2, 26.3, 27.7, 30.0,
32.3, 32.9, 33.7, 39.3, 40.3, 42.0, 53.3, 54.3, 60.3, 67.8, 69.0,
69.1, 115.9, 116.9, 120.5, 121.7, 124.8, 125.2, 125.9, 126.4,
127.5, 127.6, 129.1, 129.2, 129.6, 130.7, 130.9, 131.4, 135.0,
135.2, 137.4, 154.0, 155.9, 158.5, 170.7, 173.1, 173.6, 175.4;
ESIMS m/z: [M + H]+ 915.0 (10%), [M + 2H]2+ 457.9 (100);
HRMS–ESI m/z: [M + H]+ calcd for C53H68N7O7, 914.5175;
found, 914.5130 (100%). HPLC analysis of this compound was
also undertaken with a gradient system comprised of H2O
containing 10% CH3CN and 0.1% TFA 90:10:0.5 (A), and
CH3CN containing 0.1% TFA (B). The gradient profile was
0–3 min, linear gradient 0 to 50% B; 4–13 min, linear gradient
50 to 80% of B; 14–15 min, linear gradient 80 to 100% B; tR =
6.1 min, 96% pure.
Determination of minimum inhibitory concen-
tration (MIC)
MIC studies (Table 1) were performed on Staphylococcus
aureus wild type (ATCC 6538P), and Staphylococcus epider-
midis (ATCC 12228) in Mueller–Hinton broth (Oxoid Ltd,
England) supplemented with 50 mg/L CaCl2. As in [6], MIC
determinations for clinical isolates of Enterococcus faecium
were conducted by growth in Enterococcosal broth (Becton
Dickinson Microbiology Systems). Briefly, overnight stationary
phase cultures were diluted 1:1000 into fresh media and then in-
cubated with two-fold dilutions of compounds in media, typi-
cally with a highest concentration of 128 µg/mL, in a 96-well
plate. Plates were incubated overnight at 37 °C and the MIC
was recorded as the highest concentration at which bacterial
growth was observed.
Compound 2c (Table 2) was tested at JMI Laboratories through
Ordway Research Institute (USA) on Staphylococcus aureus
(MSSA; MRSA; VISA), S. epidermidis and E. faecium (VRE
and VSE). The microdilution reference methods (M7-A6 (2003)
Beilstein J. Org. Chem. 2012, 8, 1265–1270.
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and M11-A6 (2004)) of the CLSI/NCCLS were used. Quality
control ranges for the selected control agent vancomycin from
CLSI/NCCLS M100-S15 (2005) were used. Panels were
produced in volumes of 100 µL/well over a concentration of
0.03–32 µg/mL. A growth control was included for each dilu-
tion series. MIC results were produced by using the M7-A6 and
M11-A6 CLSI/NCCLS procedures in cation-adjusted
Mueller–Hinton broth media with supplements as required for
the test species. The compounds were initially dissolved in
DMSO and then diluted.
Supporting Information
Supporting Information File 1
Experimental procedures and associated spectroscopic data
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